8. Nordstrom T, Akre O, Aly M, et al. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic, DiS. 2018; 21(1): 57–63.
9. Bhat NR, Vetter JM, Andriole GL, et al. Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy. Urology 2018; 18: 1324–1328.
10. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998; 279: 1542–1547.
11. Vickers AJ, Savage C, O'Brien MF, et al. Systematic review of pretreatment prostate specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009; 27: 398–403.
12. Lukeš M, Záleský M, Zachoval R, Urban M, Heráček J. Prostatický specifický antigen a karcinom prostaty. Klinická onkologie 2001; 14(4): 114–118.
13. Klečka J, Běhounek P, Hora M. Současné postavení PSA v diagnostice karcinomu prostaty. Urolog. praxi 2008; 9(4): 187–189.
14. Le BV, Griffi n CR, Loeb S, et al. [-2] Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol. 2010; 183: 1355–1359.
15. Mikolajczyk SD, Millar LS, Wang TJ, et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res. 2000; 60: 756–759.
16. Mikolajczyk SD, Rittenhouse HG. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med. 2003; 52, 86–91.
17. Jansen FH, van Schaik RH, Kurstjens J. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol. 2010; 57: 921–927.
18. Guazzoni G, Nava L, Lazzeri M, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol. 2011; 60: 214–222.
19. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011; 185(5): 1650-1655.
20. Lazzeri M, Haese A, de la Taille A, et al. Serum isoform [-2] proPSA derivatives signifi cantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: a multicentric European study. Eur Urol 2013; 63(6): 986–994.
21. Král M, Hradil D, Grepl M, et al. Prostate health index (PHI) u pacientů s karcinomem prostaty a s BPH. Česká urologie 2011; 15(Suppl 2): 16–68.
22. Klečka J, Hora M, Topolčan O, et al. Je proPSA více specifický marker pro detekci karcinomu prostaty. Ces Urol 2011; 15(Suppl 2): 16–68.
23. Fuchsová R, Topolčan O, Vrzalova J, et al. Přínos stanovení [-2]proPSA v diferenciální diagnostice karcinomu prostaty. Ces Urol 18(1): 21–25.
24. Čapoun O, Sobotka R, Soukup V, et al. Prostate health index (PHI) v primární diagnostice karcinomu prostaty. Ces Urol 2014; 18(Suppl 1): 21–109.
25. Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: Data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med. 2008; 6: 19–24.
26. Stattin P, Vickers AJ, Sjoberg DD, et al. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study. Eur Urol. 2015; 68(2): 207–213.